Overview
Mermaid diagram (expand to render)
Roemmers is one of Argentina's largest and most established pharmaceutical companies, headquartered in Buenos Aires. Founded in 1929, the company has grown to become a major pharmaceutical group with operations across Latin America, focusing on innovative and generic medications for neurological disorders, cardiovascular diseases, oncology, and other therapeutic areas["@roemmers2024"].
With over 95 years of continuous operation, Roemmers represents one of the oldest pharmaceutical companies in Latin America, having weathered economic fluctuations, political changes, and regional healthcare transformations while maintaining its commitment to providing accessible medications to the Latin American population.
Company History
Founding Era (1929-1950s)
Roemmers was founded in 1929 by a group of European immigrants who brought pharmaceutical expertise to Argentina during a period of significant immigration and economic growth. The company's original focus was on importing and distributing European medications to the Argentine market.
During the 1930s and 1940s, Roemmers established its first manufacturing facilities in Buenos Aires, transitioning from a distribution company to a full-scale pharmaceutical manufacturer. This vertical integration proved crucial during World War II when imports from Europe were disrupted.
Expansion Period (1950s-1980s)
The mid-20th century saw Roemmers expand significantly:
- Establishment of dedicated research and development facilities
- Creation of generic pharmaceutical product lines
- Expansion into neighboring Latin American markets (Uruguay, Paraguay, Bolivia, Peru)
- Development of the company's first proprietary formulations
Modern Era (1990s-Present)
Following Argentina's pharmaceutical market liberalization in the 1990s, Roemmers adapted by:
- Strengthening its generic medication portfolio
- Developing partnerships with multinational pharmaceutical companies
- Expanding its presence in specialty therapeutic areas including neurology and psychiatry
- Implementing international quality standards (GMP, FDA, EMA compliant manufacturing)
Company Overview
| Attribute | Details |
|-----------|---------|
| Headquarters | Buenos Aires, Argentina |
| Founded | 1929 |
| Type | Private pharmaceutical company |
| Presence | Argentina, Uruguay, Paraguay, Bolivia, Peru |
| Products | 200+ pharmaceutical products |
| Employees | 2,000+ |
| Therapeutic Areas | Neurology, Cardiology, Oncology, Gastroenterology, Immunology |
Manufacturing Capabilities
Roemmers operates state-of-the-art manufacturing facilities in the Buenos Aires metropolitan area:
Production Facilities
- Oral Solid Dosage: Tablets, capsules,颗粒剂
- Liquid Formulations: Syrups, suspensions, solutions
- Parenterals: Injectable solutions and lyophilized products
- Topical: Creams, ointments, gels
- Biological: Limited capacity for biotech products
Quality Assurance
- GMP (Good Manufacturing Practice) compliance
- ISO 9001:2015 certification
- Regular inspections by Argentine regulatory authorities (ANMAT)
- Export quality certifications for international markets
Neurodegeneration Focus
Roemmers has established itself as a leading provider of medications for neurodegenerative diseases throughout Latin America, offering both branded and generic options for Alzheimer's disease and Parkinson's disease treatment.
Alzheimer's Disease
Roemmers markets a comprehensive range of Alzheimer's disease treatments:
Acetylcholinesterase Inhibitors
- Donepezil - Generic and branded formulations (Aricept® equivalent)
- Rivastigmine - Available in both oral and transdermal patch formulations
- Galantamine - Generic and branded extended-release options
These medications represent the first-line treatment for mild to moderate AD, working by inhibiting the acetylcholinesterase enzyme to increase synaptic acetylcholine levels[@ad-medications].
NMDA Receptor Antagonist
- Memantine - Available as monotherapy or in combination with acetylcholinesterase inhibitors
Memantine provides benefit for moderate to severe AD by modulating NMDA receptor activity, reducing excitotoxic neuronal damage[@ad-medications].
Combination Therapies
- Donepezil + Memantine fixed-dose combinations for advanced disease stages
Parkinson's Disease
The company provides essential Parkinson's disease medications covering the full spectrum of dopaminergic therapies:
Levodopa Preparations
- Levodopa/Carbidopa - Immediate-release formulations
- Levodopa/Carbidopa/Entacapone - Triple combination (Stalevo® equivalent)
- Controlled-release formulations - Extended-release levodopa preparations
- Dispersible formulations - For patients with swallowing difficulties
Levodopa remains the gold standard for PD motor symptom management, and Roemmers ensures broad access to these essential medications throughout Latin America[@pd-medications].
Dopamine Agonists
- Pramipexole - Non-ergot dopamine agonist
- Ropinirole - Oral dopamine agonist
- Rotigotine - Transdermal patch formulation
These medications provide alternative or adjunctive therapy to levodopa, particularly for early PD patients[@pd-medications].
MAO-B Inhibitors
- Selegiline - Irreversible MAO-B inhibitor
- Rasagiline - Once-daily MAO-B inhibitor
- Safinamide - Reversible MAO-B inhibitor
MAO-B inhibitors provide mild to moderate symptom control and may delay the need for levodopa in early PD[@pd-medications].
COMT Inhibitors
- Entacapone - Peripheral COMT inhibitor
- Tolcapone - Central and peripheral COMT inhibitor
These medications reduce levodopa metabolism, extending its half-life and improving motor fluctuations.
Epilepsy
Roemmers also offers antiepileptic medications relevant to neurodegeneration research and PD-related epilepsy:
- Carbamazepine - Sodium channel blocker
- Valproic acid - Broad-spectrum antiepileptic
- Levetiracetam - Novel antiepileptic mechanism
- Lamotrigine - Sodium channel blocker
- Topiramate - Multiple mechanism antiepileptic
- Gabapentin - GABA analog
- Pregabalin - GABA analog
Additional CNS Medications
The company's neurology portfolio extends to:
- Antidepressants: SSRIs, SNRIs, tricyclics
- Anxiolytics: Benzodiazepines and alternatives
- Antipsychotics: Typical and atypical for PD psychosis
- Sleep medications: Melatonin agonists, hypnotics
Regional Strategy
Roemmers operates through a multi-tiered regional strategy:
Direct Markets
- Argentina: Full commercial operations with direct sales force
- Uruguay: Direct subsidiary with local manufacturing
- Paraguay: Direct presence with distribution partners
- Bolivia: Direct commercial operations
- Peru: Direct subsidiary and manufacturing facility
Distribution Partnerships
- Chile: Distribution partnership
- Ecuador: Distribution partnership
- Colombia: Distribution partnership agreements
- Venezuela: Limited operations due to economic conditions
Manufacturing Hub
The Buenos Aires manufacturing facility serves as the regional hub, producing:
- Products for direct markets
- Products for export to partner markets
- Contract manufacturing for multinational companies
Research and Development
Roemmers maintains an active R&D program focused on:
Generic Drug Development
- Bioequivalence studies for generic drug approval
- Formulation development for improved bioavailability
- Novel delivery systems for existing molecules
Clinical Research
- Participation in international clinical trials
- Local clinical trial execution for Latin American populations
- Post-marketing surveillance studies
Academic Partnerships
- Collaborations with Argentine universities for neuroscience research
- Support for investigator-initiated studies
- Training programs for clinical researchers
Market Position
Roemmers holds a significant position in the Latin American pharmaceutical market:
Argentina
- Among top 10 pharmaceutical companies by revenue
- Leading generic medication supplier
- Key provider of CNS medications to public healthcare system
Latin America
- Presence in 5 countries with direct operations
- Distribution partnerships extending to additional markets
- Recognized as reliable regional pharmaceutical supplier
Competitive Advantages
- Local manufacturing: Reduces dependency on imports
- Established distribution network: Proven regional reach
- Brand recognition: Long-standing reputation for quality
- Pricing strategy: Accessible medications for Latin American populations
Regulatory Affairs
Roemmers maintains active regulatory affairs operations across its markets:
Argentine Operations (ANMAT)
- Product registration and maintenance
- GMP compliance and inspections
- Pharmacovigilance activities
- Advertising and promotional compliance
Regional Regulatory
- Registration in each regional market
- Harmonization with ICH guidelines where applicable
- Local regulatory affairs representatives in key markets
Social Responsibility
Roemmers engages in various social responsibility initiatives:
Healthcare Access
- Donations of essential medications to public healthcare programs
- Patient assistance programs for unaffordable medications
- Support for rare disease medication access
Education
- Medical education programs for healthcare professionals
- Support for medical conferences and publications
- University partnerships for research and training
- Environmental sustainability initiatives
- Local community support programs
- Employee volunteer programs
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Latin American Neurodegeneration Biotech](/companies/latin-american-neurodegeneration-biotech)
- [Bagó](/companies/bago)
- [Argentine Pharmaceutical Industry](/companies/argentine-pharmaceutical-industry)
- [Generic Pharmaceutical Companies](/companies/generic-pharmaceuticals-latam)
External Links
- [Roemmers Corporate Website](https://www.roemmers.com.ar/)
- [Argentine Pharmaceutical Industry Association](https://www.cifa.com.ar/)
- [ANMAT - Argentine Regulatory Authority](https://www.anmat.gob.ar/)
- [PubMed - Pharmaceutical Research Latin America](https://pubmed.ncbi.nlm.nih.gov/?term=pharmaceutical+latin+america)
- [PubMed - Alzheimer's Disease Pharmacotherapy](https://pubmed.ncbi.nlm.nih.gov/?term=Alzheimer+drug+therapy)
- [PubMed - Parkinson's Disease Pharmacotherapy](https://pubmed.ncbi.nlm.nih.gov/?term=Parkinson+drug+therapy)
References
[Roemmers Corporate Website (2024)](https://www.roemmers.com.ar/)
[Argentine Pharmaceutical Industry Association](https://www.cifa.com.ar/)
[Pharmaceutical Market in Latin America (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Current Pharmacotherapy for Alzheimer's Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33145678/)
[Parkinson's Disease Pharmacotherapy Update (2021)](https://pubmed.ncbi.nlm.nih.gov/34256789/)